by The Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The Congenital Hyperinsulinism Treatment Market is a growing market owing to rising screening testing for newborns to detect CHI at an early stage. Congenital hyperinsulinism (CHI) is a genetic condition in which the pancreas produces excess amounts of insulin. The excess insulin can cause low blood sugar (hypoglycemia), which can be severe and life threatening if not properly treated. It’s important to detect CHI early to prevent complications from recurrent low blood sugar. With increasing newborn screening programs worldwide, more cases of CHI are being diagnosed at an early stage, driving the market growth.
Market Overview:-
The congenital hyperinsulinism treatment market includes drugs and other treatment approaches for congenital hyperinsulinism (CHI) disorder. CHI disorder is caused by inappropriate and excessive insulin secretion by the pancreas. This excess insulin secretion results in episodes of very low blood sugar (hypoglycemia) in babies, children and sometimes adults. Early diagnosis and treatment helps prevent serious complications. Currently available drug treatment options include diazoxide, octreotide, verapamil, somatostatin analogues and glucagon. Surgical treatment involves partial pancreatectomy to remove insulin-secreting cells from the pancreas.
Market key trends:-
One of the key trends in the congenital hyperinsulinism treatment market is increasing research on gene therapy. Since CHI is caused by genetic mutations, targeted gene therapy holds promise to cure the root cause. Several biotech companies are conducting research to develop gene therapies using various methods like antisense oligonucleotides, gene editing etc. Gene therapy could potentially replace or reduce the need for lifelong medications. Another major trend is development of new drugs with improved efficacy and safety profiles. Many biopharma companies are developing next-gen therapies with novel mechanisms of action to better treat different sub-types of CHI.
Porter’s Analysis:-
- Threat of new entrants: The threat of new entrants is moderate. Developing novel treatment requires high capital investment and long testing time. However, large unmet need creates opportunities.
- Bargaining power of buyers: The bargaining power of buyers is moderate. Patients have few treatment options and rely on treatments. However, existence of generics exerts pricing pressure.
- Bargaining power of suppliers: Suppliers of raw materials have moderate power due to lack of substitutes and stringent regulations. However, involvement of many suppliers reduces dependency on individual supplier.
- Threat of new substitutes: The threat of new substitutes is high due to ongoing research on novel treatment approaches like gene therapy.
- Competitive rivalry: High due to large unmet need and presence of many generics driving price competition.
SWOT Analysis:-
- Strengths: High unmet medical need, increasing awareness, supportive regulatory environment for orphan diseases.
- Weaknesses: Risk of side effects, high treatment cost, lack of permanence of current drugs forcing repeat treatment.
- Opportunities: Emerging economies, ongoing research on advanced therapies, scope for combination therapies.
- Threats: Patent expiries of blockbuster drugs, pricing pressure of generics, stringent regulations.
Key Takeaways:-
The global congenital hyperinsulinism treatment market is expected to witness high growth at a CAGR of 5.7% over the forecast period, due to increasing prevalence of the disease. North America is expected to dominate the global market owing to high awareness, presence of advanced healthcare facilities and key players.
Regionally, Asia Pacific is anticipated to grow at the highest CAGR during the forecast period. Factors such as increasing healthcare expenditure, growing medical tourism industry and rising incidence of congenital defects will drive the APAC market.
Key players operating in the congenital hyperinsulinism treatment market are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio,LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd. Major players are focusing on new product launches and adopting clinical partnership strategies for sustained market positioning.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
